See all eligibility criteria
See protocol details
This study was designed to compare the efficacy and safety of an oral dual tyrosine kinase inhibitor in combination with capecitabine versus capecitabine alone in women with locally advanced or metastatic breast cancer that has not responded to previous therapy.
Show More Criteria
Show More Criteria
are designated in this study